NOVEL SYNTHESIS OF PROCESS RELATED IMPURITIES OF VALGANCICLOVIR HYDROCHLORIDE

  • Ayyakannu Arumugam Napoleon Pharmaceutical Chemistry Division, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu 632014, India
  • Gangadhara Angajala
  • Rakesh Kumar

Abstract

Objective: The present work aimed at synthesis of process related impurities of valganciclovir by using gancyclovir or monobenzyl ganciclovir as starting material comprising the following steps.

Methods: Selective hydrolysis, reaction with coupling reagent followed by hydrolysis under basic conditions and hydrogenolysis in the presence of catalyst.

Results: The final synthesized compounds 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)-3-(benzyloxy)propyl acetate 2, 2-((2-amino-6-oxo-1H-purin-9(6H)-yl) methoxy)-3-hydroxy propyl acetate 3, 2-((2-amino-6-oxo-1H-purin-9(6H)-yl) methoxy) propane-1,3-diylbis (2((benzyloxy)carbonyl) amino)-3-methylbutanoate) 6, and 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)propane-1,3-diylbis(2-amino-3-methylbutanoate) 7 were sucessfully characterized by using FT-IR, 1H NMR and LC-MS.

Conclusion: The two processes related impurities (monoacetoxy ganciclovir, 3 and bis-valine ester of ganciclovir, 7) of valganciclovir hydrochloride were reported via the formation of key intermediates (acetoxy benzyl ganciclovir, 2 and bis-Cbz-valine ester of ganciclovir, 6)

Keywords: Valganciclovir, Ganciclovir, Antiviral, Acyclic nucleosides

Downloads

Download data is not yet available.

References

1. Gorog S. Identification and determination of impurities in drugs. Elsevier; 2000. p. 1-48.
2. Nageswara Rao R, Nagaraju V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. J Pharm Biomed Anal 2003;33:335-77.
3. Gorog S. The importance and the challenges of impurity profiling in modern pharmaceutical analysis. Trends Anal Chem 2006;25:755-7.
4. Hovorka SW, Schoneich C. Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition. J Pharm Sci 2001;90:253-69.
5. Basak AK, Raw AS, Hakim AH, Furness S, Samaan NI, Gill DS. Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications. Adv Drug Delivery Rev 2007;59:64-72.
6. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000;89:781.
7. Sandor G. Chemical and analytical characterization of related organic impurities in drugs. J Pharma Biomed Anal 2003;377:852-62.
8. Riley TN. Steric aspects of drug action. Pharmacist 1998;23:40-51.
9. Roy J, Mohammad G, Banu A. Pharmaceutical analysis and stability of locally manufactured ampicillin trihydrate. Indian Drugs 1993;5:211-8.
10. Walker GJA, Hogerzeil HV, Hillgreen U. Potency of ergometrine in tropical countries. Lancet 1998;2:393.
11. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus. Clin Microbiol Rev 2000;13:83.
12. Tranos PG, Georgalas I, Founti P, Ladas I. Cytomegalovirus retinitis presenting as vasculitis in a patient with Wegener's granulomatosis. Clin Ophthamol 2008;2:961.
13. Yust I, Fox Z, Burke M. Retinal and extracular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a Euro SIDA study. Eur J Clin Microbiol Infect Dis 2004;23:550-9.
14. Curran M, Noble S. Valgancyclovir. Drugs 2001;61:1145.
15. Martin JC, Tippie MA, McGee DPC, Verheyden JPH. Synthesis and antiviral activity of various esters of 9-[1,3-dihyroxy-2-propoxy methyl] guanine. J Pharm Sci 1987;76:180.
16. Steininger C. Recent Patent Anti-Infect. Drug Discover 2007;2:53.
17. Patel K, Trivedi S, Luo S, Zhu X, Pal D, Kern ER. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of gancyclovir. Int J Pharm 2005;305:75-89.
18. Hongwu G, Ashim KM. NMR spectral data for ester prodrugs of gancyclovir. Magn Reson Chem 2000;38:696-700.
19. Reddy GM, Raju VVNKVP, Satyanarayana K, Ravindra V, Venkateshwarlu G. Alternative synthesis of Valganciclovir hydrochloride. Synth Commun 2013;43:425-30.
20. Babu KS, Srinivas P, Madavi YV, Babu I, Reddy GM, Halder P, et al. A succinct synthesis of Valganciclovir hydrochloride, a cytomegalovirus (CMV) retinitis inhibitor. Arkivoc 2011;2:199-208.
21. Babu KS, Rao MR, Goverdhan G, Srinivas P, Reddy PP, Venkateswarlu, et al. Synthesis of valganciclovir congeners. Synth Commun 2013;43:1751-8.
22. Schaeffer HJ. Purine derivatives. US patent 4360522, 1982. Chem Abstr 1980;93:186414.
23. Dvorak CA, Wren DL, Fisher LE, Axt SD, Humphreys ER, Arzeno, HB, et al. US Patent B1; 2002.
24. Rao DR, Narayanrao KR, Purushottam PV. EP Patent A1; 2007.
25. Nestor JJ, Womble SW, Maag H. US Patent; 2000.
26. Katkam S, Rajeshwar RS, Madhusudhan RG, Babu I, Srihari BK, Raghavendar RM, et al. Preparation of valganciclovir and its salts, U. S. Pat. Appl Publ; 2011.
27. Ramachandra RD, Rajendra KN, Vidyadhar PP. Preparation of valganciclovir, Eur Pat Appl; 2007.
28. Chandra HK, Yatendra K, Atulya KP, Sushil R, Mukesh KS. Preparation of ganciclovir mono-N-benzyloxycarbonyl-L-valine ester, PCT Int Appl; 2005.
29. Sharma MK, Raina S, Panda AK, Kumar Y, Khanduri CH. PCT Int Appl A2; 2005.
30. Arzeno HB. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate. Pat Appl. US5700936 A; 1997.
Statistics
843 Views | 2157 Downloads
How to Cite
Napoleon, A. A., G. Angajala, and R. Kumar. “NOVEL SYNTHESIS OF PROCESS RELATED IMPURITIES OF VALGANCICLOVIR HYDROCHLORIDE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 4, Apr. 2016, pp. 29-31, https://innovareacademics.in/journals/index.php/ijpps/article/view/6699.
Section
Original Article(s)